A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Last updated: April 17, 2018
Sponsor: Xiangya Hospital of Central South University
Overall Status: Active - Recruiting

Phase

1/2

Condition

Neoplasms

Abdominal Cancer

Carcinoid Syndrome And Carcinoid Tumours

Treatment

N/A

Clinical Study ID

NCT03511768
201801001
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Histologically and/or clinically confirmed and/or suspicious of NEN.

  2. Signed informed consent.

Exclusion

Exclusion Criteria:

  1. Claustrophobia (unable to accept PET/CT scanning)

  2. Pregnant or breast-feeding

Study Design

Total Participants: 65
Study Start date:
January 02, 2018
Estimated Completion Date:
December 30, 2020

Study Description

18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a 18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).

Connect with a study center

  • Department of PET Center,Xiangya Hospital,Central South University

    Changsha, Hunan 410008
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.